Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

2 results
12:00 AM, Jul 01, 2013  |  BioCentury | Finance

2Q Stock Wrap-Up: If it ain't broke

of Johnson & Johnson (NYSE:JNJ) to discover, develop and commercialize positive allosteric modulators (PAM) of metabotropic glutamate receptor subtype 2
mGluR2) to treat anxiety, schizophrenia and other undisclosed indications. 6/4/13 Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) 62% to …
12:00 AM, May 17, 2010  |  BioCentury | Finance

Regulatory Milestones

front and E4.2 million ($5.4 million) in R&D funding. The positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2
mGluR2 ) is in Phase I testing to treat central nervous system (CNS) disorders, including …